In the wake of Hyderabad attaining a centre place as a pharmaceutical hub, OMICS Groups is organising the 3rd international conference and exhibition on pharmacovigilance and clinical trials from October 27-29, 2014 at Hyderabad International Convention Centre (HICC). Keeping the national as well as global pharmaceutical industry growth, OMICS is planning to host this event around the theme safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management.

The conference is aimed to focus on aspects like pharmacovigilance and its challenges, role of clinical trials, clinical trials on diseases, adverse drug reactions, pharmacokinetics and pharmacodynamics, pharmacy practices and its challenges, risk management: new approaching paradigm for pharmacovigilance, clinical research and statistics, strategies for growth in pharma environment, good pharmacovigilance practice and pharmacoepidemiology, and case report in clinical trials.

Pharmacovigilance plays a significant role in ensuring drug safety by taking standard measures in the production, distribution and the delivery of medicines to the public, by upholding the dignity of people and animal that takes a voluntary part in the drug development and research.

According to various estimates, Adverse Drug Reactions occur in 10 to 20 per cent of hospital inpatients, accounting for 2 to 6 per cent of all hospital admissions, and are among top 10 causes of death in inpatients. Overall incidence of adverse drug reaction (ADR) is about 6.7 per cent and 0.32 per cent. 15 to 20 per cent of hospital budget may be spent dealing with fatal drug complications. 30 per cent to 60 per cent of ADRs are preventable.

More than 121 medicines have been withdrawn to ensure public safety for the past 40 years. Extensive use of animal and humane for the drug research in the name of clinical trial is equally controversial where animals are subjected to risk for testing the new drugs and incomplete information is often provided to the patient that volunteers for clinical trials.

At a time when the Indian pharmaceutical industry is emerging rapidly to the size of Rs.90,000 crore, growing at the rate of 12 to 14 per cent per annum, it is necessary to see that the industry is fully equipped to deliver medicines with care, ensuring drug safety. India has also emerged as the global clinical trial hub, providing a fertile ground for the experiments and pharmaceutical research. Honoring human and animal rights during clinical trials is an emerging global concern and Indian pharmaceutical industry must equip well to meet the global competition in this field.

Experts of national and international reputation including Dr K C Singhal, society of pharmacovigilance, India, Dr V Kalaiselvan, Indian Pharmcopoeia Commission, India and Dr John Barber, Dr. Reddy's Laboratories, UK are going to share their experiences at this conference as keynote speakers. The conference, through workshops, symposia, exhibition and regular sessions is all set to raise the public awareness on safe drug usages while respecting human and animal rights in the process of new drug development and pharmaceutical research.

For further details contact: Rahul Kumar, Pharmacovigilance-2014 Organizing Committee, Pharmacovigilance2014@omicsonline.us: Ph: 040-47482290.